Open access
Aug 2026
Targeting AXL Overcomes Adaptive Resistance to KRAS Inhibition in KRAS-Driven Cancer
By integrating adaptive response to KRAS inhibition with anti-tumor immunity, AXL represents a mechanistically actionable vulnerability whose inhibition deepens and prolongs responses to both allele-specific and pan-KRAS-targeted therapies.
F. Thege, A. Kramer, Norbert Kreisz et al.
· bioRxiv · 0 citations